![]() is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. It is estimated that serious genetic conditions affect one in 300 pregnancies. Foresight tests for more than 175 serious and clinically-actionable conditions. The Foresight Carrier Screen is a genetic test that identifies couples who are at increased risk of passing on inherited conditions to their children. “Importantly, the results support the wider clinical adoption of expanded carrier screening and broader insurance coverage to achieve the best health outcomes for prospective parents and their children.” “These findings provide strong evidence that ECS guides reproductive choices and impacts pregnancy outcomes,” said Dr. Of these, 35 percent of pregnancies were achieved through in vitro fertilization with preimplantation genetic testing, effectively preventing the risk of an affected pregnancy. Additionally, 166 subsequent pregnancies were reported by ARCs screened previously. Among those screened while pregnant, 37 percent elected prenatal diagnostic testing for that pregnancy, similar to the proportion of couples who choose prenatal diagnostic testing after screening positive for Down syndrome. The results show that among those screened before becoming pregnant, 77 percent planned or pursued actions to avoid having an affected offspring. 391 ARCs reported their actions and pregnancy management. This study assessed the impact of ECS on planned and actual pregnancy management in the largest population of at-risk couples (ARCs) studied to date. “The important news here is that couples used the information provided by the Foresight test to guide their decision making and help prevent the birth of an affected child.” Goldberg, M.D., chief medical officer, Myriad Women’s Health. “We now have the results from the largest-ever ECS study in parents at elevated risk of passing on an inherited condition to their children,” said James D. Foresight is the market-leading ECS and tests for more than 175 serious and clinically-actionable conditions. The key finding is that expanded carrier screening (ECS) prompted changes in pregnancy management that resulted in fewer births affected with serious genetic diseases. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that results from a large clinical utility study using the Foresight™ Carrier Screen were published in the journal Genetics in Medicine. 23, 2018 (GLOBE NEWSWIRE) - Myriad Genetics, Inc. Large Study Demonstrates that Expanded Carrier Screening Informs Couples’ Reproductive Choices and Pregnancy Management
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |